Company to maximize world-class EU-GMP operations, potentially opening future revenue- generating opportunities June 20, 2022 VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”) or the (“Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, has submitted a request... Read more
Ryan Allway June 14th, 2022 Psychedelics, Top News Vancouver, British Columbia–(Newsfile Corp. – June 14, 2022) – Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) (“Lobe” or the “Company”), a Canadian Biopharmaceutical Company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders is... Read more
Ryan Allway June 14th, 2022 Psychedelics, Top News Toronto, Ontario–(Newsfile Corp. – June 14, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, announces a request for expressions of interests from Oregon property owners who may be... Read more
Ryan Allway June 9th, 2022 Psychedelics, Top News Vancouver, British Columbia–(Newsfile Corp. – June 9, 2022) – Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (“Lobe” or the “Company”) announces that further to the Company’s June 6, 2022, news release, the record date for the six for one consolidation has... Read more
Ryan Allway June 9th, 2022 Psychedelics, Top News Toronto, Ontario–(Newsfile Corp. – June 9, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, announced today that Silo Wellness founder and chairman of the board of directors Mike... Read more
Initial data readout supports the potential effectiveness of psilocybin and psilocybin-related compounds for the treatment of Binge Eating Disorder San Diego, California — (June 9, 2022) – Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet... Read more
Clearmind Medicine Granted Patent Approval for Psychedelic-Based Alcohol Substitute in India
June 1, 2022
Ryan Allway June 1st, 2022 Psychedelics, Top News The patent was granted by India’s Office of the Controller-General of Patents, Designs and Trademarks VANCOUVER, June 1, 2022– Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the “Company“), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics... Read more
Ryan Allway May 31st, 2022 Psychedelics, Top News Toronto, Ontario–(Newsfile Corp. – May 31, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, is pleased to announce that it has executed a nonbinding letter of intent to... Read more
Ryan Allway May 27th, 2022 Psychedelics, Top News Halucenex to receive recently harvested first batch of psilocybe cubensis May 27, 2022 VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human... Read more
Ryan Allway May 23rd, 2022 Psychedelics, Top News Ehave owns approximately 9,793,754 shares of Mycotopia Therapies valued at more than $24 million, as of Friday’s closing price; Plans partial distribution to shareholders MIAMI, May 23, 2022 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a leading healthcare services... Read more
